This pattern was mirrored in melanoma tissue samples from patients treated with BRAF inhibitors, vemurafenib and dabrafenib, indicating that de-repression of TRIM16 expression in melanoma cells is a novel therapeutic approach and provides new insights into the mechanism of action of BRAF inhibitors. This evidence concerns the gene TRIM16 and melanoma.